ACRV1
- Known as:
- ACRV1
- Catalog number:
- 001040A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- ACRV1
Related genes to: ACRV1
- Gene:
- ACRV1 NIH gene
- Name:
- acrosomal vesicle protein 1
- Previous symbol:
- -
- Synonyms:
- SPACA2, SP-10, D11S4365
- Chromosome:
- 11q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-06-07
- Date modifiied:
- 2014-11-19
Related products to: ACRV1
Related articles to: ACRV1
- Psoriasis is a chronic inflammatory autoimmune skin disease for which no standardised and reliable molecular biomarkers of disease course or activity are currently available. Here, we aimed to identify serum biomarkers of psoriasis. Serum samples from 40 patients with psoriasis and 40 healthy volunteers were analysed using ELISA and Proximity Extension Assay proteomics. ELISA revealed significantly increased serum levels of AGO2 and APOA1 in psoriatic patients versus controls, with a strong association between APOA1 and psoriasis (OR = 20.72, 95% CI of 4.57-93.87, = 0.000137). Targeted serum proteomics additionally identified 35 differentially expressed proteins, including well-known psoriasis drivers (e.g., top upregulated IL17A and SERPINB4). The most downregulated was adrenomedullin (ADM, FC = -10.12). For 14 altered proteins, no previous direct associations with psoriasis were reported. Among them, DEFB103A_DEFB103B and DSG3 showed the best discrimination between psoriasis and control samples, while SERPINB4 correlated with psoriasis severity. APOA1, DEFB103A_DEFB103B, and DSG3 emerge as novel candidate circulating psoriasis biomarkers, and SERPINB4 as a biomarker of psoriasis severity. The functional role of DSG3 and other newly identified proteins (ACRV1, HAO1, ADH4, GPD1, GFER, PTGES2, DSG3, AFAP1L1, GALNT3, RASGRP2, MAP2K6, LXN, NBEAL2, and VPS54) in psoriasis requires further studies. - Source: PubMed
Publication date: 2026/06/26
Dźwigała MonikaSys DorotaŻycka-Krzesińska JoannaRybicka BeataPopławski PiotrWalecka-Herniczek IrenaPiekiełko-Witkowska AgnieszkaBogusławska Joanna - Heat stress can severely impair male reproductive performance. Endoplasmic reticulum stress (ERS) is recognized as an early cellular response to stress, which can subsequently induce inflammation and apoptosis, thereby reducing semen quality. In this study, arginine, putrescine, and 4-phenylbutyric acid (4-PBA; an ERS inhibitor) were administered by gavage to a heat-stressed ICR mouse model subjected to seven days of heat exposure, in order to evaluate their effects on testicular function and the underlying mechanisms. Supplementation with arginine, putrescine, or 4-PBA significantly ameliorated heat stress-induced testicular damage and the decline in sperm quality in male mice. Specifically, the mRNA expression of Acrv1, Izumo3, and Tjp1 was markedly upregulated. In contrast, the number of TUNEL-positive testicular cells was significantly reduced, while the mRNA expression of apoptotic markers Bax and Caspase12 was downregulated. Moreover, the expression of ERS- and inflammation-related genes (Grp78, Perk, IRE1, XBP1s, TLR4, and NF-κB) was significantly decreased. In conclusion, heat stress induces testicular dysfunction and inflammation. Both arginine and its metabolite putrescine alleviate heat stress-induced testicular impairment by reducing ERS and inflammatory responses, with arginine showing stronger protective effects than putrescine. - Source: PubMed
Publication date: 2026/05/12
Wu KunYu ChenglongLiu GuangmangZhuo YongFeng BinChe LianqiangXu ShengyuHua LunLi JianFang ZhengfengWu DeLin Yan - <b>Introduction:</b> Pancreatic cancer is still an unresolved, significant diagnostic and clinical problem. An ideal tumor marker with a high sensitivity, organ specificity, and prognostic value that correlates with tumor stages and eliminates the imperfection of preoperative serum carbohydrate antigen 19-9 (CA 19-9) concentration is still being sought.<b>Aim:</b> This study aimed to conduct a comparative analysis expression of genes <i>KRAS, DPM1, ACRV1</i>, and <i>MBD3L2</i> in the saliva of patients with pancreatic cancer (PC) and a control group (CG).<b>Material and methods:</b> The study was performed on a group of 55 patients. Group 1 consisted of 44 patients with PC, group 2 (CG) consisted of 11 individuals who were recruited among patients operated on for non-inflammatory cholelithiasis. Group 1 was divided into 2 subgroups group 1a, 19 patients with resectable pancreatic tumors, and group 1b, 25 patients with unresectable pancreatic tumors. The saliva samples were taken from patients twice, before surgery and 10 days after surgery, and the expression of genes <i>KRAS, DPM1, ACRV1</i>, and <i>MBD3L2</i> in the saliva was evaluated. Gene expression at the transcriptional level was analyzed by assessing the number of mRNA copies using the reverse transcriptase reaction and polymerase chain reaction (RT-PCR).<b>Results:</b> The revealed expression of genetic cancer biomarkers (CB) (<i>KRAS, DPM1, ACRV1, MBD3L2</i>) in saliva was statistically significantly higher in the PC group in comparison to CG. There was a statistically significant decrease in the <i>KRAS</i> gene expression and a statistically significant increase in the <i>MBD3L2</i> expression in patients in subgroup 1a, 10 days after resection procedures. The revealed serum concentration of CA 19-9 was significantly higher in subgroup 1b in comparison to subgroup 1a. Although higher gene expression of <i>KRAS, DPM1</i>, and <i>MBD3L2 </i>was observed in subgroup 1b, no statistical significance was obtained. A statistically significant correlation between <i>DPM1</i> expression and serum CA 19-9 level in the PC group was observed. There were statistically significant differences in <i>KRAS </i>and <i>DPM1</i> expression depending on the tumor stage in the TNM/UICC classification regarding to T and N category. A significant difference in <i>MBD3L2</i> expression was observed in N category. A statistically significant increase in the expression of <i>KRAS, DPM1</i>, and <i>MBD3L2 </i>was observed in the case of neoplastic infiltration of blood vessels, and a significant increase in the expression of <i>KRAS</i> and <i>MBD3L2 <i/>in the case of neoplastic infiltration of nerve fibers.<b>Conclusions:</b> Presented findings suggest the usefulness of the salivary transcriptome profiles in distinguishing patients with PC from healthy controls but its usefulness in the differential diagnosis between resectable and unresectable PC is limited. However, more studies on a large population are needed to support our result. - Source: PubMed
Ciosek JakubDranka-Bojarowska DariaLewiński AdamLampe Paweł - Ovarian cancer (OC) remains a leading cause of gynecological cancer-related mortality, largely due to metabolic reprogramming and aggressive progression. Zinc finger protein 280A (ZNF280A), a poorly characterized transcriptional regulator, has recently been implicated in tumorigenesis, but its mechanistic role in OC remains undefined. Here, we identify ZNF280A as an oncogenic driver that promotes OC progression through transcriptional regulation of acrosomal vesicle protein 1 (ACRV1) and activation of the PI3K/AKT signaling pathway. ZNF280A expression was markedly elevated in OC tissues and cell lines and correlated with advanced clinicopathologic features and poor patient survival. Functional assays revealed that ZNF280A knockdown inhibited OC cell proliferation, migration, and tumorigenesis while inducing apoptosis both in vitro and in vivo. Mechanistically, ZNF280A enhanced ACRV1 transcription by interacting with the transcription factor CUX2, thereby facilitating its recruitment to the ACRV1 promoter. Elevated ZNF280A or ACRV1 expression activated PI3K/AKT signaling and increased glycolytic enzyme expression (PKM2 and LDHA), glucose uptake, lactate production, ATP generation, and extracellular acidification rate, whereas pharmacological inhibition of AKT or glycolysis abrogated these effects. Collectively, our findings establish ZNF280A as a key regulator of metabolic reprogramming in OC through the CUX2-ACRV1-PI3K/AKT axis, highlighting this pathway as a potential therapeutic target in ovarian cancer. - Source: PubMed
Publication date: 2025/12/01
Zhu DaweiChen PuyuYu LiangbinGao ShuaiLiu YiPan SilinLi Li - To explore the role of nuclear receptor-binding SET-domain protein 1 (NSD1) in the pathogenesis of nonobstructive azoospermia (NOA) by regulating the expressions of relevant genes. - Source: PubMed
Zhuang XuanCai Zhen-XinYang Yu-FengLi Zhi-Ming